These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 38919490)
41. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. Doga M; Bonadonna S; Burattin A; Giustina A Ann Oncol; 2001; 12 Suppl 2():S89-94. PubMed ID: 11762359 [TBL] [Abstract][Full Text] [Related]
42. Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide. Puglisi S; Ferraù F; Ragonese M; Spagnolo F; Cannavò S Front Endocrinol (Lausanne); 2020; 11():28. PubMed ID: 32117056 [TBL] [Abstract][Full Text] [Related]
43. "Micromegaly": Acromegaly with apparently normal GH, an entity on its own? Vilar L; Naves LA; Martins MRA; Ribeiro-Oliveira A Best Pract Res Clin Endocrinol Metab; 2024 May; 38(3):101878. PubMed ID: 38519400 [TBL] [Abstract][Full Text] [Related]
44. Growth hormone pulsatility in acromegaly following radiotherapy. Peacey SR; Shalet SM Pituitary; 1999 Jun; 2(1):63-9. PubMed ID: 11081174 [TBL] [Abstract][Full Text] [Related]
45. MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose. Hage M; Janot C; Salenave S; Chanson P; Kamenický P Eur J Endocrinol; 2021 May; 184(6):R261-R268. PubMed ID: 33830942 [TBL] [Abstract][Full Text] [Related]
46. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly. Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115 [TBL] [Abstract][Full Text] [Related]
47. 3D Volumetric Measurements of GH Secreting Adenomas Correlate with Baseline Pituitary Function, Initial Surgery Success Rate, and Disease Control. Tirosh A; Papadakis GZ; Chittiboina P; Lyssikatos C; Belyavskaya E; Keil M; Lodish MB; Stratakis CA Horm Metab Res; 2017 Jun; 49(6):440-445. PubMed ID: 28472827 [TBL] [Abstract][Full Text] [Related]
48. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly. Cardinal T; Collet C; Wedemeyer M; Singer PA; Weiss M; Zada G; Carmichael JD Front Endocrinol (Lausanne); 2021; 12():743052. PubMed ID: 34867787 [TBL] [Abstract][Full Text] [Related]
49. Diagnosis of acromegaly in a patient with type 1 diabetes mellitus. Hofmann EA; Polonsky KS; Weiss RE Endocr Pract; 2002; 8(2):113-8. PubMed ID: 11942776 [TBL] [Abstract][Full Text] [Related]
50. Acromegaly associated with type 2 diabetes showing normal IGF-1 levels under poorly controlled glycemia. Lim DJ; Kwon HS; Cho JH; Kim SH; Choi YH; Yoon KH; Cha BY; Lee KW; Son HY; Kang SK Endocr J; 2007 Aug; 54(4):537-41. PubMed ID: 17575366 [TBL] [Abstract][Full Text] [Related]
53. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529 [TBL] [Abstract][Full Text] [Related]
54. Absence of immunostaining for growth hormone in a subset of patients with acromegaly. Schroeder JL; Spiotta AM; Fleseriu M; Prayson RA; Hamrahian AH; Weil RJ Pituitary; 2014 Apr; 17(2):103-8. PubMed ID: 23475513 [TBL] [Abstract][Full Text] [Related]
55. Octreotide as primary therapy for acromegaly. Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397 [TBL] [Abstract][Full Text] [Related]
56. Ectopic acromegaly due to a GH-secreting pituitary adenoma in the sphenoid sinus: a case report and review of the literature. Ramírez C; Hernández-Ramirez LC; Espinosa-de-los-Monteros AL; Franco JM; Guinto G; Mercado M BMC Res Notes; 2013 Oct; 6():411. PubMed ID: 24119925 [TBL] [Abstract][Full Text] [Related]
57. Hemangiopericytoma in the setting of acromegaly. Elias WJ; Hussaina IM; Chadduck JB; Jane JA; Laws ER; Lopes MB Endocr Pathol; 2002; 13(3):251-61. PubMed ID: 12446926 [TBL] [Abstract][Full Text] [Related]
58. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment. Campana C; Cocchiara F; Corica G; Nista F; Arvigo M; Amarù J; Rossi DC; Zona G; Ferone D; Gatto F J Clin Endocrinol Metab; 2021 Mar; 106(3):789-801. PubMed ID: 33236108 [TBL] [Abstract][Full Text] [Related]
59. Gender- and age-related differences in the endocrine parameters of acromegaly. Colao A; Amato G; Pedroncelli AM; Baldelli R; Grottoli S; Gasco V; Petretta M; Carella C; Pagani G; Tambura G; Lombardi G J Endocrinol Invest; 2002 Jun; 25(6):532-8. PubMed ID: 12109625 [TBL] [Abstract][Full Text] [Related]
60. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly. Bastemir M; Akin F; Yaylali GF Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]